Stock Research for ARFXF

ARFXF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ARFXF Stock Chart & Research Data

The ARFXF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARFXF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARFXF Due diligence Resources & Stock Charts

The ARFXF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARFXF Detailed Price Forecast - CNN Money CNN View ARFXF Detailed Summary - Google Finance
Yahoo View ARFXF Detailed Summary - Yahoo! Finance Zacks View ARFXF Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ARFXF Trends & Analysis - Trade-Ideas Barrons View ARFXF Major Holders - Barrons
NASDAQ View ARFXF Call Transcripts - NASDAQ Seeking View ARFXF Breaking News & Analysis - Seeking Alpha
Spotlight View ARFXF Annual Report - CompanySpotlight.com OTC Report View ARFXF OTC Short Report - OTCShortReport.com
TradeKing View ARFXF Fundamentals - TradeKing Charts View ARFXF SEC Filings - Bar Chart
WSJ View Historical Prices for ARFXF - The WSJ Morningstar View Performance/Total Return for ARFXF - Morningstar
MarketWatch View the Analyst Estimates for ARFXF - MarketWatch CNBC View the Earnings History for ARFXF - CNBC
StockMarketWatch View the ARFXF Earnings - StockMarketWatch MacroAxis View ARFXF Buy or Sell Recommendations - MacroAxis
Bullish View the ARFXF Bullish Patterns - American Bulls Short Pains View ARFXF Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ARFXF Stock Mentions - StockTwits PennyStocks View ARFXF Stock Mentions - PennyStockTweets
Twitter View ARFXF Stock Mentions - Twitter Invest Hub View ARFXF Investment Forum News - Investor Hub
Yahoo View ARFXF Stock Mentions - Yahoo! Message Board Seeking Alpha View ARFXF Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ARFXF - SECform4.com Insider Cow View Insider Transactions for ARFXF - Insider Cow
CNBC View ARFXF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARFXF - OTC Markets
Yahoo View Insider Transactions for ARFXF - Yahoo! Finance NASDAQ View Institutional Holdings for ARFXF - NASDAQ


Stock Charts

FinViz View ARFXF Stock Insight & Charts - FinViz.com StockCharts View ARFXF Investment Charts - StockCharts.com
BarChart View ARFXF Stock Overview & Charts - BarChart Trading View View ARFXF User Generated Charts - Trading View




Latest Financial News for ARFXF


ProMIS Neurosciences Announces Second Quarter 2018 Results
Posted on Tuesday August 14, 2018

ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2018. "Over the first half of 2018, we focused on three key priorities to advance our business", stated ProMIS Executive Chairman, Eugene Williams.


ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018
Posted on Tuesday August 07, 2018

ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018


PMN.TO: More Support for Toxic Oligomers
Posted on Wednesday August 01, 2018

The highlight of the 2018 Alzheimer`s Association International Conference (AAIC) was the surprise announcement a few weeks ago by Biogen and Eisai regarding their Phase II study of BAN2401. The results of this trial that were initially hinted at on July 5th, demonstrated improvements in cognition and a dose-dependent reduction in amyloid plaques that was statistically significant. Biogen’s analysis followed weak initial findings that used new approaches to evaluate efficacy.


ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018'
Posted on Tuesday July 31, 2018

Key conference theme: targeting toxic amyloid-beta oligomers offers renewed hope for treatment of Alzheimer`s disease  TORONTO and CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.